Clinical, medical and diagnostics
Provepharm is advancing surgical precision with plans to launch two innovative dyes in 2026, supporting minimally invasive and fluorescence-guided robotic surgery. The move marks a strategic shift toward R&D-driven growth and cutting-edge visualisation solutions.
The company has partnered with Sagent Pharmaceuticals to distribute Bludigo® - an FDA-approved injectable indigo carmine - alongside its upcoming diagnostic dyes in the US, using Sagent’s market expertise and commercial reach. Internationally, Provepharm will roll out its new dyes through its global distributor network.
“Our goal is to create the most advanced range of surgical dyes by 2030,” said Hélène Thomas, Deputy CEO of Provepharm. “We are combining our deep R&D expertise with next-generation fluorescence technology to deliver highly selective, reliable, and stable dyes for surgeons worldwide.”
Provepharm’s ‘Smart Dyes’ platform will focus on enhanced purity, stability, and visualisation performance, helping surgeons see more clearly during complex procedures, particularly in oncology. The company’s approach emphasises efficiency, precision, and patient safety, building on 25 years of expertise in high-quality medical dyes.
The medical dye market is expanding rapidly, with demand fuelled by increasingly complex surgeries and widespread adoption of imaging and fluorescence-guided techniques. Provepharm is positioning itself at the forefront of this growth, combining scientific innovation with global partnerships to reshape surgical visualisation.
More information online
.jpg)
